Dacemazine

Dacemazine is a pharmacological agent that belongs to the class of antipsychotic drugs. It is primarily used in the treatment of psychiatric disorders such as schizophrenia and other types of psychosis.

Pharmacology[edit | edit source]

Dacemazine acts by blocking dopamine receptors in the brain, specifically the D2 subtype. This reduces the overactivity of dopamine, which is thought to be a contributing factor in the development of psychotic symptoms. Dacemazine also has some affinity for the D1 subtype, but its clinical significance is less clear.

Clinical Use[edit | edit source]

Dacemazine is used in the management of acute and chronic psychosis, including schizophrenia. It can help to reduce symptoms such as hallucinations, delusions, and disordered thinking. In some cases, it may also be used to manage severe anxiety or agitation.

Side Effects[edit | edit source]

Like all antipsychotic drugs, dacemazine can cause side effects. These may include drowsiness, dizziness, dry mouth, constipation, and blurred vision. In some cases, it may also cause movement disorders such as tardive dyskinesia.

History[edit | edit source]

Dacemazine was first synthesized in the 1970s as part of a search for new antipsychotic agents. It was found to have potent antipsychotic activity in preclinical studies, and has since been used in clinical practice.